INCRUSE ELLIPTA INHALATION POWDER 62.5 MCG/DOSE

GLAXOSMITHKLINE PTE LTD

GLAXOSMITHKLINE PTE LTD

Therapeutic

Prescription Only

POWDER, METERED

**Dosage and Administration** Pharmaceutical form: Inhalation powder, pre-dispensed. _INCRUSE ELLIPTA_ is for oral inhalation only. _INCRUSE ELLIPTA_ should be administered once daily at the same time of the day each day. **Adults** The recommended dose is one inhalation of _INCRUSE ELLIPTA_ once daily. **Children** Use in patients less than 18 years of age is not relevant given the indication for this product. **Elderly** No dosage adjustment is required in patients over 65 years (see _Pharmacokinetics – Special Patient Populations_ – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_). **Renal impairment** No dosage adjustment is required in patients with renal impairment (see _Pharmacokinetics — Special Patient Populations_ – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_). **Hepatic impairment** No dosage adjustment is required in patients with mild or moderate hepatic impairment. _INCRUSE ELLIPTA_ has not been studied in patients with severe hepatic impairment (see _Pharmacokinetics — Special Patient Populations_ – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_).